Hybrid cholecystokinin (CCK) antagonists: new implications in the design and modification of CCK antagonists.
Kerwin
J F
JF
Neuroscience Research Division, Abbott Laboratories, Abbott Park, Illinois 60064.
Nadzan
A M
AM
Kopecka
H
H
Lin
C W
CW
Miller
T
T
Witte
D
D
Burt
S
S
D001569:Benzodiazepines / Q000138:chemical synthesis / Q000494:pharmacology*; D001570:Benzodiazepinones / Q000138:chemical synthesis / Q000494:pharmacology; D055598:Chemical Phenomena; D002621:Chemistry; D002766:Cholecystokinin / Q000037:antagonists & inhibitors*; D020109:Devazepide; D015195:Drug Design; D005973:Glutamine / Q000031:analogs & derivatives; D008968:Molecular Conformation; D011377:Proglumide / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000494:pharmacology; D011949:Receptors, Cholecystokinin / Q000187:drug effects; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D001570:Benzodiazepinones; D011949:Receptors, Cholecystokinin; D005973:Glutamine; D001569:Benzodiazepines; D002766:Cholecystokinin; D011377:Proglumide; D020109:Devazepide; C048181:lorglumide